Amylyx Pharmaceuticals (AMLX) EBITDA (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) EBITDA from Mar 31, 2021 to Mar 31, 2026. The TTM Amylyx Pharmaceuticals (AMLX) EBITDA is -$159M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Amylyx Pharmaceuticals (AMLX) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -30.85% |
| 3 Years TTM | +0.83% |
| 5 Years TTM | +65.32% |
| All Time TTM | +7.81% |
Annual EBITDA change of Amylyx Pharmaceuticals (AMLX)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$44M | -71.41% |
| 2025 | -$153M | -51.32% |
| 2024 | -$314M | -886.74% |
| 2023 | $40M | -119.86% |
| 2022 | -$201M | +143.04% |
| 2021 | -$83M | N/A |